U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07037420) titled 'ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly' on May 27.
Brief Summary: The primary objective of this study is to evaluate the efficacy of 15-week treatment with ALXN2420 versus placebo for decreasing insulin-like growth factor IGF-1 levels, when administered in combination with somatostatin analog (SSA) therapy to adult participants with acromegaly.
Study Start Date: Oct. 17, 2025
Study Type: INTERVENTIONAL
Condition:
Acromegaly
Intervention:
DRUG: ALXN2420
ALXN2420 will be administered via subcutaneous (SC) injection
DRUG: Placebo
Placebo will be administered via SC inje...